PEDIATRICS Vol. 98 No. 4 October 1996, pp. 706-713
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldman, A. P.
Right arrow Articles by Macrae, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldman, A. P.
Right arrow Articles by Macrae, D. J.

Four Patterns of Response to Inhaled Nitric Oxide for Persistent Pulmonary Hypertension of the Newborn

Allan P. Goldman MRCP1, Robert C. Tasker FRCP1, Sheila G. Haworth FACC1, Paul E. Sigston FRCA1, and Duncan J. Macrae FRCA1

1 Cardiac and Paediatric Intensive Care Units, Great Ormond Street Hospital for Children, London, United Kingdom

Objective. To determine the clinical role of inhaled nitric oxide (iNO) in the treatment of persistent pulmonary hypertension of the newborn (PPHN).

Study Design. Prospective open observational clinical study.

Setting. A regional cardiac and pediatric intensive care unit.

Methods. Twenty-five consecutive near-term neonates (>35 weeks gestation) with severe PPHN (oxygenation index [OI]> 25) were given a trial of iNO of 20 ppm for 20 minutes. Neonates who showed a greater than 20% improvement in Pao 2 as well as a decrease in the OI to below 40 were defined as responders and continued on this therapy.

Results. Four patterns of response emerged to the iNO therapy: Pattern 1 neonates (n = 2) did not respond to the initial trial of iNO—one survived. Pattern 2 neonates (n = 9) responded to the initial trial of iNO, but failed to sustain this response over 36 hours, as defined by a rise in the OI to >40. Six survived, five with extracorporeal membrane oxygenation. Pattern 3 neonates (n = 11) responded to the initial trial of iNO, sustained this response, and were successfully weaned from iNO within 5 days—all survived to discharge. Pattern 4 neonates (n = 3) responded to the initial trial of iNO, but developed a sustained dependence on iNO for 3 to 6 weeks. All three died and lung histology revealed severe pulmonary hypoplasia and dysplasia. These neonates (pattern 4) not only required iNO for a longer period of time than did the sustained responders (pattern 3), but they required significantly higher doses of iNO during their first 5 days of iNO therapy.

Conclusions. Early responses to iNO may not be sustained. Neonates with pulmonary hypoplasia and dysplasia may have a decreased sensitivity and differing time course of response to iNO when compared with patients who have PPHN in fully developed lungs.

Submitted on August 14, 1995
Accepted on November 10, 1995




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
J. Gien, G. J. Seedorf, V. Balasubramaniam, N. Markham, and S. H. Abman
Intrauterine Pulmonary Hypertension Impairs Angiogenesis In Vitro: Role of Vascular Endothelial Growth Factor Nitric Oxide Signaling
Am. J. Respir. Crit. Care Med., December 1, 2007; 176(11): 1146 - 1153.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
E. Resnik, J. Herron, M. Keck, D. Sukovich, B. Linden, and D. N. Cornfield
Chronic intrauterine pulmonary hypertension selectively modifies pulmonary artery smooth muscle cell gene expression
Am J Physiol Lung Cell Mol Physiol, March 1, 2006; 290(3): L426 - L433.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
M. Hinton, L. Mellow, A. J. Halayko, A. Gutsol, and S. Dakshinamurti
Hypoxia induces hypersensitivity and hyperreactivity to thromboxane receptor agonist in neonatal pulmonary arterial myocytes
Am J Physiol Lung Cell Mol Physiol, February 1, 2006; 290(2): L375 - L384.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. A. Krasuski, J. J. Warner, A. Wang, J. K. Harrison, V. F. Tapson, and T. M. Bashore
Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology
J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2204 - 2211.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
I. Schulze-Neick, D. J. Penny, M. L. Rigby, C. Morgan, A. Kelleher, P. Collins, J. Li, A. Bush, E. A. Shinebourne, and A. N. Redington
L-Arginine and Substance P Reverse the Pulmonary Endothelial Dysfunction Caused by Congenital Heart Surgery
Circulation, August 17, 1999; 100(7): 749 - 755.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
D. L. Wessel, I. Adatia, L. J. Van Marter, J. E. Thompson, J. W. Kane, A. R. Stark, and S. Kourembanas
Improved Oxygenation in a Randomized Trial of Inhaled Nitric Oxide for Persistent Pulmonary Hypertension of the Newborn
Pediatrics, November 1, 1997; 100(5): e7 - e7.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
N. FINER
Inhaled nitric oxide in neonates
Arch. Dis. Child. Fetal Neonatal Ed., September 1, 1997; 77(2): 81F - 84.
[Full Text]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
H. Aly, R. Sahni, and J.-T. Wung
Weaning strategy with inhaled nitric oxide treatment in persistent pulmonary hypertension of the newborn
Arch. Dis. Child. Fetal Neonatal Ed., March 1, 1997; 76(2): 118F - 122.
[Abstract] [Full Text]